The University of Texas System

Yale University

Nuvera Biosciences, Inc.

Christos Hatzis

Lajos Pusztai

W Fraser Symmans

William Fraser Symmans

Bruno Sinn

Chunxiao Fu

Rosanna Lau

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESRI) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.

Targeted measure of transcriptional activity related to hormone receptors

Disclosed is a method for determining survival and relapse of a patient undergoing therapy for a tumor by determining a residual cancer burden index based on the bidimensional diameters of a primary tumor bed of said tumor in a resection specimen, the proportion of the primary tumor bed area that contains invasive carcinoma, the number of regional lymph nodes containing metastatic carcinoma, the diameter of the largest metastasis in an regional lymph node; and the fractional reduction in lymph node size with each added positive lymph node.

Method of measuring residual cancer and predicting patient survival

Growing community of inventors

Melrose, MA, United States of America

Christos Hatzis